Diabetic Neuropathy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Diabetes is the most common cause of peripheral neuropathy in the world. More than half of patients with diabetes have neuropathy, and half of patients with neuropathy have diabetes. Diabetic neuropathy is a major cause of disability and health care expense. This article reviews the various forms of diabetic neuropathy with a focus on diagnosis and treatment. RECENT FINDINGS: Diabetes causes a wide variety of peripheral nerve problems. These can be divided into chronic neuropathies, of which distal symmetric polyneuropathy is the most common, and acute neuropathies, such as diabetic amyotrophy. There is growing evidence suggesting that prediabetic levels of hyperglycemia and other consequences of obesity and dyslipidemia contribute to neuropathy risk. Evolving literature suggests that many of the acute diabetic neuropathies are related to inflammatory mechanisms. An important exception is treatment-related neuropathy, previously known as "insulin neuritis". SUMMARY: While disease-altering therapy continues to prove elusive, our understanding of basic disease mechanisms is improving, and new diagnostic and research tools will hopefully lead to novel therapies for distal symmetric diabetic polyneuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“The Steno-2 trial demonstrated that aggressive therapy to normalize hypertension and lipid abnormalities in patients with type 2 diabetes reduced the risk of coronary, cerebral, or peripheral vascular occlusive disease but also reduced the risk of nephropathy, retinopathy, and autonomic neuropathy, independent of gluc…”
BackgroundHarris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
de Jager, J., Kooy, A., Lehert, P., Wulffele, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010) · BMJ · doi:10.1136/bmj.c2181 · Cited by 702
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Self-citationIntraepidermal nerve fiber density at the distal leg: a worldwide normative reference study
Lauria, G., Bakkers, M., Schmitz, C., Lombardi, R., Penza, P., Devigili, G., Smith, A. G., Hsieh, S., Mellgren, S. I., Umapathi, T., et al. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00271.x · Cited by 518 · cited 1×
“Age and gender normative data are published.(10) The Toronto Consensus Conference accepted use of validated measures of small fiber function (eg, IENFD) in lieu of NCSs in patients with suspected small fiber neuropathy with normal NCSs.”
MethodSelf-citationIncreased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy
Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1448 · Cited by 364
Self-citationWile, D. J., & Toth, C. (2010) · Diabetes Care · doi:10.2337/dc09-0606 · Cited by 283
Treatment-induced diabetic neuropathy: A reversible painful autonomic neuropathy
Gibbons, C. H., & Freeman, R. (2010) · Annals of Neurology · doi:10.1002/ana.21952 · Cited by 213 · cited 3×
“This disorder may be prevented by a more gradual initiation of insulin therapy in patients who are chronically nonadherent or whose diabetes is poorly controlled.(49) FIGURE 3-9 Patients with type 1 (red) and type 2 (black) diabetes are both at risk for developing treatment-related painful neuropathy.”
BackgroundInfluentialBonora, E., Kiechl, S., Oberhollenzer, F., Egger, G., Bonadonna, R. C., Muggeo, M., & Willeit, J. (2000) · Diabetologia · doi:10.1007/s001250050024 · Cited by 140 · cited 1×
“Patients with prediabetes are at increased risk for cardiovascular and peripheral vascular occlusive disease, independent of risk for diabetes.(41) Because of these risks, the ADA recommends screening for prediabetes and metabolic syndrome in all patients more than 45 years old and in younger patients with a BMI more…”
BackgroundThe diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy
Smith, A. G., & Singleton, J. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.1021 · Cited by 95 · cited 2×
“Vitamin B12 level, serum protein electrophoresis, and immunofixation should be assessed in all patients with neuropathy, and an evaluation for connective tissue disease (eg, Sjögren syndrome) or infection (eg, hepatitis C or HIV) should be pursued in appropriately selected at-risk patients.(14)”
BackgroundSelf-citation
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Diabetic peripheral neuropathy: Current perspective and future directions
Singh, R., Kishore, L., & Kaur, N. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.005 · Cited by 400
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3939-0 · Cited by 337
Jensen, T. S., Karlsson, P., Gylfadottir, S. S., Andersen, S. T., Bennett, D. L., Tankisi, H., Finnerup, N. B., Terkelsen, A. J., Khan, K., Themistocleous, A. C., et al. (2021) · Brain · doi:10.1093/brain/awab079 · Cited by 265
Metadata
- Authors
- Smith, A. G., & Singleton, J. R.
- Venue
- Continuum
- Published
- 2012-02
- Volume
- 18
- Issue
- 1
- Pages
- 60-84
- ISSN
- 1080-2371 (ISSN-L)
- 1538-6899
- OpenAlex
- W4255362988
- Cited by
- 58
- References
- 14
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.